{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T21:02:30Z","timestamp":1788037350780,"version":"build-2784847793"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With 54 new drugs and seven cellular and gene therapy products, the approvals by the US Food and Drug Administration (FDA) recovered 2023 from the 2022 dent back to the levels of 2020\u20132021. As in previous years of this annual review, we assign these new drugs to one of three levels of innovation: first drug against a condition (\u201cfirst-in-indication\u201d), first drug using a novel molecular mechanism (\u201cfirst-in-class\u201d), and \u201cnext-in-class,\u201d i.e., a drug using an already exploited molecular mechanism. We identify four (7%) \u201cfirst-in-indication,\u201d 22 (36%) \u201cfirst-in-class,\u201d and 35 (57%) \u201cnext-in-class\u201d drugs. By treatment area, rare diseases (54%) and cancer drugs (23%) were once again the most prevalent (and partly overlapping) therapeutic areas. Other continuing trends were the use of accelerated regulatory approval pathways and the reliance on biopharmaceuticals (biologics). 2023 marks the approval of a first therapy based on CRISPR\/Cas9 gene editing.<\/jats:p>","DOI":"10.1007\/s00210-024-03063-1","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T06:02:02Z","timestamp":1711432922000},"page":"2949-2970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023"],"prefix":"10.1007","volume":"397","author":[{"given":"Gizem","family":"Kayki-Mutlu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zinnet Sevval","family":"Aksoyalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leszek","family":"Wojnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"3063_CR1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3389\/fncel.2018.00188","volume":"12","author":"R Abeti","year":"2018","unstructured":"Abeti R, Baccaro A, Esteras N, Giunti P (2018) Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich\u2019s ataxia models. Front Cell Neurosci 12:188. https:\/\/doi.org\/10.3389\/fncel.2018.00188","journal-title":"Front Cell Neurosci"},{"key":"3063_CR2","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","volume":"268","author":"D Adams","year":"2021","unstructured":"Adams D, Ando Y, Beirao JM, Coelho T, Gertz MA, Gillmore JD, Hawkins PN, Lousada I, Suhr OB, Merlini G (2021) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol 268:2109\u20132122. https:\/\/doi.org\/10.1007\/s00415-019-09688-0","journal-title":"J Neurol"},{"key":"3063_CR3","doi-asserted-by":"publisher","first-page":"e46912","DOI":"10.7759\/cureus.46912","volume":"15","author":"S Alam","year":"2023","unstructured":"Alam S, Khan SJ, Lee CYF, Zaidi SAT, Murtaza SF (2023) Type 1 diabetes mellitus management and islet cell therapy: a new chapter in patient care. Cureus 15:e46912. https:\/\/doi.org\/10.7759\/cureus.46912","journal-title":"Cureus"},{"key":"3063_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3324\/haematol.2019.240754","volume":"106","author":"AJ Ambinder","year":"2021","unstructured":"Ambinder AJ, Levis M (2021) Potential targeting of FLT3 acute myeloid leukemia. Haematologica 106:671\u2013681. https:\/\/doi.org\/10.3324\/haematol.2019.240754","journal-title":"Haematologica"},{"key":"3063_CR5","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.03.018","volume":"63","author":"A Andrikopoulou","year":"2022","unstructured":"Andrikopoulou A, Chatzinikolaou S, Panourgias E, Kaparelou M, Liontos M, Dimopoulos MA, Zagouri F (2022) The emerging role of capivasertib in breast cancer. Breast 63:157\u2013167. https:\/\/doi.org\/10.1016\/j.breast.2022.03.018","journal-title":"Breast"},{"key":"3063_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2204919","volume":"387","author":"R Arbel","year":"2022","unstructured":"Arbel R, Wolff Sagy Y, Hoshen M, Battat E, Lavie G, Sergienko R, Friger M, Waxman JG, Dagan N, Balicer R, Ben-Shlomo Y, Peretz A, Yaron S, Serby D, Hammerman A, Netzer D (2022) Nirmatrelvir use and severe Covid-19 outcomes during the Omicron Surge. N Engl J Med 387:790\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa2204919","journal-title":"N Engl J Med"},{"key":"3063_CR7","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1200\/JCO.20.02272","volume":"39","author":"A Bardia","year":"2021","unstructured":"Bardia A, Kaklamani V, Wilks S, Weise A, Richards D, Harb W, Osborne C, Wesolowski R, Karuturi M, Conkling P, Bagley RG, Wang Y, Conlan MG, Kabos P (2021) Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. J Clin Oncol 39:1360\u20131370. https:\/\/doi.org\/10.1200\/JCO.20.02272","journal-title":"J Clin Oncol"},{"key":"3063_CR8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","volume":"103","author":"MA Baum","year":"2023","unstructured":"Baum MA, Langman C, Cochat P, Lieske JC, Moochhala SH, Hamamoto S, Satoh H, Mourani C, Ariceta G, Torres A, Wolley M, Belostotsky V, Forbes TA, Groothoff J, Hayes W, T\u00f6nshoff B, Takayama T, Rosskamp R, Russell K, Zhou J, Amrite A, Hoppe B (2023) PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int 103:207\u2013217. https:\/\/doi.org\/10.1016\/j.kint.2022.07.025","journal-title":"Kidney Int"},{"key":"3063_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"3063_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00280-023-04550-7","volume":"92","author":"JH Beumer","year":"2023","unstructured":"Beumer JH, Foldi J (2023) Pharmacology and pharmacokinetics of elacestrant. Cancer Chemother Pharmacol 92:157\u2013163. https:\/\/doi.org\/10.1007\/s00280-023-04550-7","journal-title":"Cancer Chemother Pharmacol"},{"key":"3063_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, D\u00edaz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"key":"3063_CR12","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1200\/JCO.22.00338","volume":"40","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garcia Saenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cortes J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A (2022) Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial. J Clin Oncol 40:3246\u20133256. https:\/\/doi.org\/10.1200\/JCO.22.00338","journal-title":"J Clin Oncol"},{"key":"3063_CR13","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s40265-022-01788-y","volume":"82","author":"HA Blair","year":"2022","unstructured":"Blair HA (2022) Valoctocogene roxaparvovec: first approval. Drugs 82:1505\u20131510. https:\/\/doi.org\/10.1007\/s40265-022-01788-y","journal-title":"Drugs"},{"key":"3063_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40265-023-01886-5","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023a) Cipaglucosidase alfa: first approval. Drugs 83:739\u2013745. https:\/\/doi.org\/10.1007\/s40265-023-01886-5","journal-title":"Drugs"},{"key":"3063_CR15","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s40265-023-01911-7","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023b) Efbemalenograstim alfa: first approval. Drugs 83:1125\u20131130. https:\/\/doi.org\/10.1007\/s40265-023-01911-7","journal-title":"Drugs"},{"key":"3063_CR16","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA (2023c) Tofersen: first approval. Drugs 83:1039\u20131043. https:\/\/doi.org\/10.1007\/s40265-023-01904-6","journal-title":"Drugs"},{"key":"3063_CR17","doi-asserted-by":"publisher","first-page":"102427","DOI":"10.1016\/j.ctrv.2022.102427","volume":"109","author":"DW Blayney","year":"2022","unstructured":"Blayney DW, Schwartzberg L (2022) Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review. Cancer Treat Rev 109:102427. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102427","journal-title":"Cancer Treat Rev"},{"key":"3063_CR18","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s10545-018-0185-0","volume":"41","author":"L Borgwardt","year":"2018","unstructured":"Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, Heron B, Geraci S, Ardig\u00f2 D, Cattaneo F, Fogh J, Van den Hout JMH, Beck M, Jones SA, Tylki-Szymanska A, Haugsted U, Lund AM (2018) Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. J Inherit Metab Dis 41:1215\u20131223. https:\/\/doi.org\/10.1007\/s10545-018-0185-0","journal-title":"J Inherit Metab Dis"},{"key":"3063_CR19","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA (2014) Paroxysmal nocturnal hemoglobinuria. Blood 124:2804\u20132811. https:\/\/doi.org\/10.1182\/blood-2014-02-522128","journal-title":"Blood"},{"key":"3063_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12096-0","author":"BJ Byrne","year":"2023","unstructured":"Byrne BJ, Schoser B, Kishnani PS, Bratkovic D, Clemens PR, Goker-Alpan O, Ming X, Roberts M, Vorgerd M, Sivakumar K, van der Ploeg AT, Goldman M, Wright J, Holdbrook F, Jain V, Benjamin ER, Johnson F, Das SS, Wasfi Y, Mozaffar T (2023) Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I\/II study (ATB200-02). J Neurol. https:\/\/doi.org\/10.1007\/s00415-023-12096-0","journal-title":"J Neurol"},{"key":"3063_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","volume":"15","author":"HT Chifotides","year":"2022","unstructured":"Chifotides HT, Bose P, Verstovsek S (2022) Momelotinib: an emerging treatment for myelofibrosis patients with anemia. J Hematol Oncol 15:7. https:\/\/doi.org\/10.1186\/s13045-021-01157-4","journal-title":"J Hematol Oncol"},{"key":"3063_CR22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s40120-022-00414-z","volume":"12","author":"T Coelho","year":"2023","unstructured":"Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, Barroso FA, Dasgupta NR, Jung SW, Schneider E, Viney NJ, Dyck PJB, Ando Y, Gillmore JD, Khella S, Gertz MA, Obici L, Berk JL (2023) Characteristics of patients with hereditary transthyretin amyloidosis-polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an open-label phase 3 study of eplontersen. Neurol Ther 12:267\u2013287. https:\/\/doi.org\/10.1007\/s40120-022-00414-z","journal-title":"Neurol Ther"},{"key":"3063_CR23","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1126\/science.adg1899","volume":"378","author":"J Couzin-Frankel","year":"2022","unstructured":"Couzin-Frankel J, Piller C (2022) Alzheimer\u2019s drug stirs excitement-and concerns. Science 378:1030\u20131031. https:\/\/doi.org\/10.1126\/science.adg1899","journal-title":"Science"},{"key":"3063_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CCO.0000000000000952","volume":"35","author":"J Crawford","year":"2023","unstructured":"Crawford J, Oswalt C (2023) The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps. Curr Opin Oncol 35:241\u2013247. https:\/\/doi.org\/10.1097\/CCO.0000000000000952","journal-title":"Curr Opin Oncol"},{"key":"3063_CR25","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1182\/bloodadvances.2023010407","volume":"7","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski S, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL (2023a) Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. Blood Adv 7:5210\u20135214. https:\/\/doi.org\/10.1182\/bloodadvances.2023010407","journal-title":"Blood Adv"},{"key":"3063_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-023-02273-z","volume":"29","author":"ZD Crees","year":"2023","unstructured":"Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jimenez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, Garcia-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF (2023b) Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med 29:869\u2013879. https:\/\/doi.org\/10.1038\/s41591-023-02273-z","journal-title":"Nat Med"},{"key":"3063_CR27","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.tips.2023.03.005","volume":"44","author":"S Dayalan Naidu","year":"2023","unstructured":"Dayalan Naidu S, Dinkova-Kostova AT (2023) Omaveloxolone (Skyclarys(TM)) for patients with Friedreich\u2019s ataxia. Trends Pharmacol Sci 44:394\u2013395. https:\/\/doi.org\/10.1016\/j.tips.2023.03.005","journal-title":"Trends Pharmacol Sci"},{"key":"3063_CR28","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"CL Deal","year":"2022","unstructured":"Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, Kim HS, Ko C, Malievskiy O, Cara JF, Roland CL, Taylor CT, Valluri SR, Wajnrajch MP, Pastrak A, Miller BS (2022) Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab 107:e2717\u2013e2728. https:\/\/doi.org\/10.1210\/clinem\/dgac220","journal-title":"J Clin Endocrinol Metab"},{"key":"3063_CR29","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","volume":"388","author":"G D'Haens","year":"2023","unstructured":"D\u2019Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE (2023) Mirikizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 388:2444\u20132455. https:\/\/doi.org\/10.1056\/NEJMoa2207940","journal-title":"N Engl J Med"},{"key":"3063_CR30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Daprodustat: first approval. Drugs 80:1491\u20131497. https:\/\/doi.org\/10.1007\/s40265-020-01384-y","journal-title":"Drugs"},{"key":"3063_CR31","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40265-023-01921-5","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S (2023a) Beremagene geperpavec: first approval. Drugs 83:1131\u20131135. https:\/\/doi.org\/10.1007\/s40265-023-01921-5","journal-title":"Drugs"},{"key":"3063_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01954-w","author":"S Dhillon","year":"2023","unstructured":"Dhillon S (2023b) Elranatamab: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01954-w","journal-title":"Drugs"},{"key":"3063_CR33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","volume":"83","author":"S Dhillon","year":"2023","unstructured":"Dhillon S (2023c) Zavegepant: first approval. Drugs 83:825\u2013831. https:\/\/doi.org\/10.1007\/s40265-023-01885-6","journal-title":"Drugs"},{"key":"3063_CR34","doi-asserted-by":"publisher","unstructured":"Dubinsky MC, Jairath V, Feagan BG, Naegeli AN, Tuttle J, Morris N, Shan M, Arora V, Lissoos T, Agada N, Hibi T, Sands BE (2023) Changes in health-related quality of life and associations with improvements in clinical efficacy: a phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterol 10. https:\/\/doi.org\/10.1136\/bmjgast-2023-001115","DOI":"10.1136\/bmjgast-2023-001115"},{"key":"3063_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","volume":"83","author":"S Duggan","year":"2023","unstructured":"Duggan S, Al-Salama ZT (2023) Leniolisib: first approval. Drugs 83:943\u2013948. https:\/\/doi.org\/10.1007\/s40265-023-01895-4","journal-title":"Drugs"},{"key":"3063_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13000-023-01357-1","volume":"18","author":"APH Dyrbekk","year":"2023","unstructured":"Dyrbekk APH, Warsame AA, Suhrke P, Ludahl MO, Moe JO, Eide IJZ, Lund-Iversen M, Brustugun OT (2023) Evaluation of ROS1 expression and rearrangements in a large cohort of early-stage lung cancer. Diagn Pathol 18:70. https:\/\/doi.org\/10.1186\/s13000-023-01357-1","journal-title":"Diagn Pathol"},{"key":"3063_CR37","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/phar.2802","volume":"43","author":"A El-Ghali","year":"2023","unstructured":"El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ (2023) Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections. Pharmacotherapy 43:502\u2013513. https:\/\/doi.org\/10.1002\/phar.2802","journal-title":"Pharmacotherapy"},{"key":"3063_CR38","doi-asserted-by":"publisher","first-page":"102625","DOI":"10.1016\/j.ebiom.2019.102625","volume":"52","author":"PJ Engelberts","year":"2020","unstructured":"Engelberts PJ, Hiemstra IH, de Jong B, Schuurhuis DH, Meesters J, Beltran Hernandez I, Oostindie SC, Neijssen J, van den Brink EN, Horbach GJ, Verploegen S, Labrijn AF, Salcedo T, Schuurman J, Parren P, Breij ECW (2020) DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine 52:102625. https:\/\/doi.org\/10.1016\/j.ebiom.2019.102625","journal-title":"EBioMedicine"},{"key":"3063_CR39","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/bjh.17580","volume":"194","author":"H Fassel","year":"2021","unstructured":"Fassel H, McGuinn C (2021) Haemophilia: factoring in new therapies. Br J Haematol 194:835\u2013850. https:\/\/doi.org\/10.1111\/bjh.17580","journal-title":"Br J Haematol"},{"key":"3063_CR40","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","volume":"83","author":"JE Frampton","year":"2023","unstructured":"Frampton JE (2023) Epcoritamab: first approval. Drugs 83:1331\u20131340. https:\/\/doi.org\/10.1007\/s40265-023-01930-4","journal-title":"Drugs"},{"key":"3063_CR41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.ophtha.2023.05.030","volume":"130","author":"IB Gaddie","year":"2023","unstructured":"Gaddie IB, Donnenfeld ED, Karpecki P, Vollmer P, Berdy GJ, Peterson JD, Simmons B, Edell ARP, Whitson WE, Ciolino JB, Baba SN, Holdbrook M, Trevejo J, Meyer J, Yeu E (2023) Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (saturn-2). Ophthalmology 130:1015\u20131023. https:\/\/doi.org\/10.1016\/j.ophtha.2023.05.030","journal-title":"Ophthalmology"},{"key":"3063_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","volume":"171","author":"ML Gauci","year":"2022","unstructured":"Gauci ML, Aristei C, Becker JC, Blom A, Bataille V, Dreno B, Del Marmol V, Forsea AM, Fargnoli MC, Grob JJ, Gomes F, Hauschild A, Hoeller C, Harwood C, Kelleners-Smeets N, Kaufmann R, Lallas A, Malvehy J, Moreno-Ramirez D, Peris K, Pellacani G, Saiag P, Stratigos AJ, Vieira R, Zalaudek I, van Akkooi ACJ, Lorigan P, Garbe C, Lebbe C, European Dermatology Forum tEAoD-O, the European Organization for R, Treatment of C (2022) Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - update 2022. Eur J Cancer 171:203\u2013231. https:\/\/doi.org\/10.1016\/j.ejca.2022.03.043","journal-title":"Eur J Cancer"},{"key":"3063_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.bbmt.2013.10.013","volume":"20","author":"S Giralt","year":"2014","unstructured":"Giralt S, Costa L, Schriber J, Dipersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant 20:295\u2013308. https:\/\/doi.org\/10.1016\/j.bbmt.2013.10.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"3063_CR44","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00240-023-01453-3","volume":"51","author":"DS Goldfarb","year":"2023","unstructured":"Goldfarb DS, Lieske JC, Groothoff J, Schalk G, Russell K, Yu S, Vrhnjak B (2023) Nedosiran in primary hyperoxaluria subtype 3: results from a phase I, single-dose study (PHYOX4). Urolithiasis 51:80. https:\/\/doi.org\/10.1007\/s00240-023-01453-3","journal-title":"Urolithiasis"},{"key":"3063_CR45","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJMoa2210140","volume":"388","author":"M Gounder","year":"2023","unstructured":"Gounder M, Ratan R, Alcindor T, Schoffski P, van der Graaf WT, Wilky BA, Riedel RF, Lim A, Smith LM, Moody S, Attia S, Chawla S, D\u2019Amato G, Federman N, Merriam P, Van Tine BA, Vincenzi B, Benson C, Bui NQ, Chugh R, Tinoco G, Charlson J, Dileo P, Hartner L, Lapeire L, Mazzeo F, Palmerini E, Reichardt P, Stacchiotti S, Bailey HH, Burgess MA, Cote GM, Davis LE, Deshpande H, Gelderblom H, Grignani G, Loggers E, Philip T, Pressey JG, Kummar S, Kasper B (2023) Nirogacestat, a gamma-secretase inhibitor for desmoid tumors. N Engl J Med 388:898\u2013912. https:\/\/doi.org\/10.1056\/NEJMoa2210140","journal-title":"N Engl J Med"},{"key":"3063_CR46","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1913556","volume":"383","author":"MP Griffin","year":"2020","unstructured":"Griffin MP, Yuan Y, Takas T, Domachowske JB, Madhi SA, Manzoni P, Sim\u00f5es EAF, Esser MT, Khan AA, Dubovsky F, Villafana T, DeVincenzo JP (2020) Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 383:415\u2013425. https:\/\/doi.org\/10.1056\/NEJMoa1913556","journal-title":"N Engl J Med"},{"key":"3063_CR47","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jimd.12602","volume":"46","author":"N Guffon","year":"2023","unstructured":"Guffon N, Konstantopoulou V, Hennermann JB, Muschol N, Bruno I, Tummolo A, Ceravolo F, Zardi G, Ballabeni A, Lund A (2023) Long-term safety and efficacy of velmanase alfa treatment in children under 6 years of age with alpha-mannosidosis: a phase 2, open label, multicenter study. J Inherit Metab Dis 46:705\u2013719. https:\/\/doi.org\/10.1002\/jimd.12602","journal-title":"J Inherit Metab Dis"},{"key":"3063_CR48","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","volume":"79","author":"M Guglieri","year":"2022","unstructured":"Guglieri M, Clemens PR, Perlman SJ, Smith EC, Horrocks I, Finkel RS, Mah JK, Deconinck N, Goemans N, Haberlova J, Straub V, Mengle-Gaw LJ, Schwartz BD, Harper AD, Shieh PB, De Waele L, Castro D, Yang ML, Ryan MM, McDonald CM, Tulinius M, Webster R, McMillan HJ, Kuntz NL, Rao VK, Baranello G, Spinty S, Childs AM, Sbrocchi AM, Selby KA, Monduy M, Nevo Y, Vilchez-Padilla JJ, Nascimento-Osorio A, Niks EH, de Groot IJM, Katsalouli M, James MK, van den Anker J, Damsker JM, Ahmet A, Ward LM, Jaros M, Shale P, Dang UJ, Hoffman EP (2022) Efficacy and Safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial. JAMA Neurol 79:1005\u20131014. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2480","journal-title":"JAMA Neurol"},{"key":"3063_CR49","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, Agostini B, Chen H, Feeney G, Steimer M, Kapadia B, Sridhar K, Quesada Sanchez L, Gonzalez F, Van Ligten M, Parry TJ, Chitra S, Kammerman LA, Krishnan S, Marinkovich MP (2022) Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med 387:2211\u20132219. https:\/\/doi.org\/10.1056\/NEJMoa2206663","journal-title":"N Engl J Med"},{"key":"3063_CR50","doi-asserted-by":"publisher","first-page":"e13019","DOI":"10.1111\/jne.13019","volume":"34","author":"H Gunduz-Bruce","year":"2022","unstructured":"Gunduz-Bruce H, Takahashi K, Huang MY (2022) Development of neuroactive steroids for the treatment of postpartum depression. J Neuroendocrinol 34:e13019. https:\/\/doi.org\/10.1111\/jne.13019","journal-title":"J Neuroendocrinol"},{"key":"3063_CR51","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, Reitze N, Sarma N, Bagci IS, Sridhar K, Kakarla V, Yenamandra VK, O\u2019Malley M, Prisco M, Tufa SF, Keene DR, South AP, Krishnan SM, Marinkovich MP (2022) In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med 28:780\u2013788. https:\/\/doi.org\/10.1038\/s41591-022-01737-y","journal-title":"Nat Med"},{"key":"3063_CR52","doi-asserted-by":"publisher","first-page":"1249492","DOI":"10.3389\/fphar.2023.1249492","volume":"14","author":"MU Haider","year":"2023","unstructured":"Haider MU, Furqan M, Mehmood Q (2023) Daprodustat: a potential game-changer in renal anemia therapy-A perspective. Front Pharmacol 14:1249492. https:\/\/doi.org\/10.3389\/fphar.2023.1249492","journal-title":"Front Pharmacol"},{"key":"3063_CR53","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/dom.13833","volume":"21","author":"YC Halvorsen","year":"2019","unstructured":"Halvorsen YC, Walford GA, Massaro J, Aftring RP, Freeman MW (2019a) A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes. Diabetes Obes Metab 21:2496\u20132504. https:\/\/doi.org\/10.1111\/dom.13833","journal-title":"Diabetes Obes Metab"},{"key":"3063_CR54","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1111\/dom.13801","volume":"21","author":"YD Halvorsen","year":"2019","unstructured":"Halvorsen YD, Lock JP, Zhou W, Zhu F, Freeman MW (2019b) A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab 21:2248\u20132256. https:\/\/doi.org\/10.1111\/dom.13801","journal-title":"Diabetes Obes Metab"},{"key":"3063_CR55","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/dom.13928","volume":"22","author":"YD Halvorsen","year":"2020","unstructured":"Halvorsen YD, Walford G, Thurber T, Russell H, Massaro M, Freeman MW (2020) A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes Obes Metab 22:566\u2013573. https:\/\/doi.org\/10.1111\/dom.13928","journal-title":"Diabetes Obes Metab"},{"key":"3063_CR56","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1111\/dom.15192","volume":"25","author":"YD Halvorsen","year":"2023","unstructured":"Halvorsen YD, Conery AL, Lock JP, Zhou W, Freeman MW (2023a) Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 25:2954\u20132962. https:\/\/doi.org\/10.1111\/dom.15192","journal-title":"Diabetes Obes Metab"},{"key":"3063_CR57","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/dom.14875","volume":"25","author":"YD Halvorsen","year":"2023","unstructured":"Halvorsen YD, Lock JP, Frias JP, Tinahones FJ, Dahl D, Conery AL, Freeman MW (2023b) A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab 25:293\u2013301. https:\/\/doi.org\/10.1111\/dom.14875","journal-title":"Diabetes Obes Metab"},{"key":"3063_CR58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, Dagan R, Yuan Y, Baca Cots M, Bosheva M, Madhi SA, Muller WJ, Zar HJ, Brooks D, Grenham A, W\u00e4hlby Hamr\u00e9n U, Mankad VS, Ren P, Takas T, Abram ME, Leach A, Griffin MP, Villafana T (2022) Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N Engl J Med 386:837\u2013846. https:\/\/doi.org\/10.1056\/NEJMoa2110275","journal-title":"N Engl J Med"},{"key":"3063_CR59","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","volume":"386","author":"J Hammond","year":"2022","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Sim\u00f3n-Campos A, Pypstra R, Rusnak JM (2022) Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 386:1397\u20131408. https:\/\/doi.org\/10.1056\/NEJMoa2118542","journal-title":"N Engl J Med"},{"key":"3063_CR60","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1007\/s00277-022-04933-5","volume":"101","author":"B Han","year":"2022","unstructured":"Han B, Ji J, Zhang B, Bai H, Zhou D, Feng F, Huang Y, Zhu H, Chen L, Wu Z, Jiang X, Li X, Jia Q, Chang Q, Pan H, Peng H, Zheng W, Huang H, Chen Z, Yang C, Chen M, Du B, Zhang S (2022) The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria. Ann Hematol 101:2537\u20132539. https:\/\/doi.org\/10.1007\/s00277-022-04933-5","journal-title":"Ann Hematol"},{"key":"3063_CR61","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1002\/hed.27452","volume":"45","author":"J Han","year":"2023","unstructured":"Han J, Zeng N, Tian K, Liu Z, She L, Wang Z, He J, Chen N (2023) First-line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: an updated network meta-analysis and cost-effectiveness analysis. Head Neck 45:2246\u20132258. https:\/\/doi.org\/10.1002\/hed.27452","journal-title":"Head Neck"},{"key":"3063_CR62","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1080\/14656566.2022.2113384","volume":"23","author":"A Hatashima","year":"2022","unstructured":"Hatashima A, Karami M, Shadman M (2022) Approved and emerging Bruton\u2019s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia. Expert Opin Pharmacother 23:1545\u20131557. https:\/\/doi.org\/10.1080\/14656566.2022.2113384","journal-title":"Expert Opin Pharmacother"},{"key":"3063_CR63","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/s0140-6736(23)00569-x","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, Inrig J, Komers R, Mercer A, Noronha IL, Rheault MN, Rote W, Rovin B, Trachtman H, Trimarchi H, Wong MG, Perkovic V (2023) Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401:1584\u20131594. https:\/\/doi.org\/10.1016\/s0140-6736(23)00569-x","journal-title":"Lancet"},{"key":"3063_CR64","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40291-023-00662-1","volume":"27","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023a) Omidubicel: first approval. Mol Diagn Ther 27:637\u2013642. https:\/\/doi.org\/10.1007\/s40291-023-00662-1","journal-title":"Mol Diagn Ther"},{"key":"3063_CR65","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s40265-023-01953-x","volume":"83","author":"YA Heo","year":"2023","unstructured":"Heo YA (2023b) Zuranolone: first approval. Drugs 83:1559\u20131567. https:\/\/doi.org\/10.1007\/s40265-023-01953-x","journal-title":"Drugs"},{"key":"3063_CR66","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1111\/pde.15378","volume":"40","author":"M Hordinsky","year":"2023","unstructured":"Hordinsky M, Hebert AA, Gooderham M, Kwon O, Murashkin N, Fang H, Harada K, Law E, Wajsbrot D, Takiya L, Zwillich SH, Wolk R, Tran H (2023) Efficacy and safety of ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO phase 2b\/3 randomized, double-blind, placebo-controlled trial. Pediatr Dermatol 40:1003\u20131009. https:\/\/doi.org\/10.1111\/pde.15378","journal-title":"Pediatr Dermatol"},{"key":"3063_CR67","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40265-023-01848-x","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023a) Bexagliflozin: first approval. Drugs 83:447\u2013453. https:\/\/doi.org\/10.1007\/s40265-023-01848-x","journal-title":"Drugs"},{"key":"3063_CR68","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023b) Elacestrant: first approval. Drugs 83:555\u2013561. https:\/\/doi.org\/10.1007\/s40265-023-01861-0","journal-title":"Drugs"},{"key":"3063_CR69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40265-023-01851-2","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023c) Lecanemab: first approval. Drugs 83:359\u2013365. https:\/\/doi.org\/10.1007\/s40265-023-01851-2","journal-title":"Drugs"},{"key":"3063_CR70","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s40265-023-01962-w","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023d) Motixafortide: first approval. Drugs 83:1635\u20131643. https:\/\/doi.org\/10.1007\/s40265-023-01962-w","journal-title":"Drugs"},{"key":"3063_CR71","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s40265-023-01933-1","volume":"83","author":"SM Hoy","year":"2023","unstructured":"Hoy SM (2023e) Rozanolixizumab: first approval. Drugs 83:1341\u20131347. https:\/\/doi.org\/10.1007\/s40265-023-01933-1","journal-title":"Drugs"},{"key":"3063_CR72","doi-asserted-by":"publisher","unstructured":"Hudu SA, Elmigdadi F, Qtaitat AA, Almehmadi M, Alsaiari AA, Allahyani M, Aljuaid A, Salih M, Alghamdi A, Alrofaidi MA, Abida, Imran M (2023) Trofinetide for Rett syndrome: highlights on the development and related inventions of the first USFDA-approved treatment for rare pediatric unmet medical need. J Clin Med 12. https:\/\/doi.org\/10.3390\/jcm12155114","DOI":"10.3390\/jcm12155114"},{"key":"3063_CR73","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","volume":"128","author":"GJ Jaffe","year":"2021","unstructured":"Jaffe GJ, Westby K, Csaky KG, Mon\u00e9s J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA (2021) C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: a randomized pivotal phase 2\/3 trial. Ophthalmology 128:576\u2013586. https:\/\/doi.org\/10.1016\/j.ophtha.2020.08.027","journal-title":"Ophthalmology"},{"key":"3063_CR74","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1182\/blood-2021-146178","volume":"138","author":"J-H Jang","year":"2021","unstructured":"Jang J-H, Weyne J, Chaudhari U, Harari O, Miller J, Dain B, Meagher KA, Rodgers ML, Perlee L, Morton L, Weinreich DM, Yancopoulos GD, Griffin M (2021) Pozelimab, a human monoclonal antibody against complement factor C5, provided inhibition of intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Blood 138:1128. https:\/\/doi.org\/10.1182\/blood-2021-146178","journal-title":"Blood"},{"key":"3063_CR75","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1182\/bloodadvances.2022006960","volume":"6","author":"JH Jang","year":"2022","unstructured":"Jang JH, Wong L, Ko BS, Yoon SS, Li K, Baltcheva I, Nidamarthy PK, Chawla R, Junge G, Yap ES (2022) Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. Blood Adv 6:4450\u20134460. https:\/\/doi.org\/10.1182\/bloodadvances.2022006960","journal-title":"Blood Adv"},{"key":"3063_CR76","doi-asserted-by":"publisher","first-page":"77S","DOI":"10.1097\/00004714-199006001-00014","volume":"10","author":"SW Jenkins","year":"1990","unstructured":"Jenkins SW, Robinson DS, Fabre LF Jr, Andary JJ, Messina ME, Reich LA (1990) Gepirone in the treatment of major depression. J Clin Psychopharmacol 10:77S-85S. https:\/\/doi.org\/10.1097\/00004714-199006001-00014","journal-title":"J Clin Psychopharmacol"},{"key":"3063_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2023.08.008","author":"J Jin","year":"2023","unstructured":"Jin J, Zhong XB (2023) ASO drug Qalsody (tofersen) targets amyotrophic lateral sclerosis. Trends Pharmacol Sci. https:\/\/doi.org\/10.1016\/j.tips.2023.08.008","journal-title":"Trends Pharmacol Sci"},{"key":"3063_CR78","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.kint.2023.02.019","volume":"103","author":"KL Johansen","year":"2023","unstructured":"Johansen KL, Cobitz AR, Singh AK, Macdougall IC, Lopes RD, Obrador GT, Kovesdy CP, Israni R, Jha V, Okoro T, Sprys M, Jolly S, Lindsay AC, Bhatt P, Camejo RR, Keeley T, Cizman B, Wheeler DC (2023) The ASCEND-NHQ randomized trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis chronic kidney disease. Kidney Int 103:1180\u20131192. https:\/\/doi.org\/10.1016\/j.kint.2023.02.019","journal-title":"Kidney Int"},{"key":"3063_CR79","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1210\/clinem\/dgad058","volume":"108","author":"KA Johnson","year":"2023","unstructured":"Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C, Lee M, Santoro N (2023) Efficacy and safety of fezolinetant in moderate to severe vasomotor symptoms associated with menopause: a phase 3 RCT. J Clin Endocrinol Metab 108:1981\u20131997. https:\/\/doi.org\/10.1210\/clinem\/dgad058","journal-title":"J Clin Endocrinol Metab"},{"key":"3063_CR80","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s40265-023-01884-7","volume":"83","author":"C Kang","year":"2023","unstructured":"Kang C (2023) Retifanlimab: first approval. Drugs 83:731\u2013737. https:\/\/doi.org\/10.1007\/s40265-023-01884-7","journal-title":"Drugs"},{"key":"3063_CR81","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","volume":"386","author":"J Kanter","year":"2022","unstructured":"Kanter J, Walters MC, Krishnamurti L, Mapara MY, Kwiatkowski JL, Rifkin-Zenenberg S, Aygun B, Kasow KA, Pierciey FJ Jr, Bonner M, Miller A, Zhang X, Lynch J, Kim D, Ribeil JA, Asmal M, Goyal S, Thompson AA, Tisdale JF (2022) Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med 386:617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa2117175","journal-title":"N Engl J Med"},{"key":"3063_CR82","doi-asserted-by":"publisher","first-page":"2153410","DOI":"10.1080\/19420862.2022.2153410","volume":"15","author":"H Kaplon","year":"2023","unstructured":"Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM (2023) Antibodies to watch in 2023. Mabs 15:2153410. https:\/\/doi.org\/10.1080\/19420862.2022.2153410","journal-title":"Mabs"},{"key":"3063_CR83","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/s1473-3099(23)00184-6","volume":"23","author":"KS Kaye","year":"2023","unstructured":"Kaye KS, Shorr AF, Wunderink RG, Du B, Poirier GE, Rana K, Miller A, Lewis D, O\u2019Donnell J, Chen L, Reinhart H, Srinivasan S, Isaacs R, Altarac D (2023) Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis 23:1072\u20131084. https:\/\/doi.org\/10.1016\/s1473-3099(23)00184-6","journal-title":"Lancet Infect Dis"},{"key":"3063_CR84","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00210-021-02085-3","volume":"394","author":"G Kayki-Mutlu","year":"2021","unstructured":"Kayki-Mutlu G, Michel MC (2021) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn-Schmiedeberg\u2019s Arch Pharmacol 394:839\u2013852. https:\/\/doi.org\/10.1007\/s00210-021-02085-3","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"3063_CR85","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00210-022-02250-2","volume":"395","author":"G Kayki-Mutlu","year":"2022","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2022) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021. Naunyn Schmiedebergs Arch Pharmacol 395:867\u2013885. https:\/\/doi.org\/10.1007\/s00210-022-02250-2","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3063_CR86","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s00210-023-02465-x","volume":"396","author":"G Kayki-Mutlu","year":"2023","unstructured":"Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, Michel MC (2023) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022. Naunyn Schmiedebergs Arch Pharmacol 396:1619\u20131632. https:\/\/doi.org\/10.1007\/s00210-023-02465-x","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3063_CR87","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3324\/haematol.2022.280801","volume":"108","author":"S Kayser","year":"2023","unstructured":"Kayser S, Levis MJ (2023) The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica 108:308\u2013320. https:\/\/doi.org\/10.3324\/haematol.2022.280801","journal-title":"Haematologica"},{"key":"3063_CR88","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40265-019-01076-2","volume":"79","author":"SJ Keam","year":"2019","unstructured":"Keam SJ (2019) Toripalimab: first global approval. Drugs 79:573\u2013578. https:\/\/doi.org\/10.1007\/s40265-019-01076-2","journal-title":"Drugs"},{"key":"3063_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01975-5","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023a) Gepirone extended-release: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01975-5","journal-title":"Drugs"},{"key":"3063_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01964-8","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023b) Momelotinib: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01964-8","journal-title":"Drugs"},{"key":"3063_CR91","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023c) Pirtobrutinib: first approval. Drugs 83:547\u2013553. https:\/\/doi.org\/10.1007\/s40265-023-01860-1","journal-title":"Drugs"},{"key":"3063_CR92","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023d) Talquetamab: first approval. Drugs 83:1439\u20131445. https:\/\/doi.org\/10.1007\/s40265-023-01945-x","journal-title":"Drugs"},{"key":"3063_CR93","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023e) Trofinetide: first approval. Drugs 83:819\u2013824. https:\/\/doi.org\/10.1007\/s40265-023-01883-8","journal-title":"Drugs"},{"key":"3063_CR94","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01986-2","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023f) Vamorolone: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01986-2","journal-title":"Drugs"},{"key":"3063_CR95","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/bjd\/ljac001","volume":"188","author":"JS Kern","year":"2023","unstructured":"Kern JS, Sprecher E, Fernandez MF, Schauer F, Bodemer C, Cunningham T, L\u00f6we S, Davis C, Sumeray M, Bruckner AL, Murrell DF (2023) Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol 188:12\u201321. https:\/\/doi.org\/10.1093\/bjd\/ljac001","journal-title":"Br J Dermatol"},{"key":"3063_CR96","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/s41571-023-00787-6","volume":"20","author":"D Killock","year":"2023","unstructured":"Killock D (2023) Newly diagnosed AML: quizartinib improves OS. Nat Rev Clin Oncol 20:504. https:\/\/doi.org\/10.1038\/s41571-023-00787-6","journal-title":"Nat Rev Clin Oncol"},{"key":"3063_CR97","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1093\/annonc\/mdt220","volume":"24","author":"HR Kim","year":"2013","unstructured":"Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC (2013) The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol 24:2364\u20132370. https:\/\/doi.org\/10.1093\/annonc\/mdt220","journal-title":"Ann Oncol"},{"key":"3063_CR98","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/s0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, Mesinkovska NA, Zwillich SH, Napatalung L, Wajsbrot D, Fayyad R, Freyman A, Mitra D, Purohit V, Sinclair R, Wolk R (2023) Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet 401:1518\u20131529. https:\/\/doi.org\/10.1016\/s0140-6736(23)00222-2","journal-title":"Lancet"},{"key":"3063_CR99","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/d41573-023-00050-8","volume":"22","author":"K Kingwell","year":"2023","unstructured":"Kingwell K (2023) First CRISPR therapy seeks landmark approval. Nat Rev Drug Discov 22:339\u2013341. https:\/\/doi.org\/10.1038\/d41573-023-00050-8","journal-title":"Nat Rev Drug Discov"},{"key":"3063_CR100","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/nrneph.2015.82","volume":"11","author":"MJ Koury","year":"2015","unstructured":"Koury MJ, Haase VH (2015) Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 11:394\u2013410. https:\/\/doi.org\/10.1038\/nrneph.2015.82","journal-title":"Nat Rev Nephrol"},{"key":"3063_CR101","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/bjh.16456","volume":"189","author":"EE Ladikou","year":"2020","unstructured":"Ladikou EE, Chevassut T, Pepper CJ, Pepper AG (2020) Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia. Br J Haematol 189:815\u2013825. https:\/\/doi.org\/10.1111\/bjh.16456","journal-title":"Br J Haematol"},{"key":"3063_CR102","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1097\/MS9.0000000000000843","volume":"85","author":"MO Larik","year":"2023","unstructured":"Larik MO, Iftekhar MA, Syed BU, Ansari O, Ansari M (2023) Nasal spray (Zavegepant) for migraines: a mini-review. Ann Med Surg (lond) 85:2787\u20132790. https:\/\/doi.org\/10.1097\/MS9.0000000000000843","journal-title":"Ann Med Surg (lond)"},{"key":"3063_CR103","doi-asserted-by":"publisher","unstructured":"Lavacchi D, Roviello G, Guidolin A, Romano S, Venturini J, Caliman E, Vannini A, Giommoni E, Pellegrini E, Brugia M, Pillozzi S, Antonuzzo L (2023) Evaluation of fruquintinib in the continuum of care of patients with colorectal cancer. Int J Mol Sci 24. https:\/\/doi.org\/10.3390\/ijms24065840","DOI":"10.3390\/ijms24065840"},{"key":"3063_CR104","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s0140-6736(23)00085-5","volume":"401","author":"S Lederman","year":"2023","unstructured":"Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M, Neal-Perry G (2023) Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet 401:1091\u20131102. https:\/\/doi.org\/10.1016\/s0140-6736(23)00085-5","journal-title":"Lancet"},{"key":"3063_CR105","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee A (2023) Omaveloxolone: first approval. Drugs 83:725\u2013729. https:\/\/doi.org\/10.1007\/s40265-023-01874-9","journal-title":"Drugs"},{"key":"3063_CR106","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodriotaguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29:2259\u20132267. https:\/\/doi.org\/10.1038\/s41591-023-02528-9","journal-title":"Nat Med"},{"key":"3063_CR107","doi-asserted-by":"publisher","first-page":"338 e331","DOI":"10.1016\/j.jtct.2023.01.031","volume":"29","author":"C Lin","year":"2023","unstructured":"Lin C, Schwarzbach A, Sanz J, Montesinos P, Stiff P, Parikh S, Brunstein C, Cutler C, Lindemans CA, Hanna R, Koh LP, Jagasia MH, Valcarcel D, Maziarz RT, Keating AK, Hwang WYK, Rezvani AR, Karras NA, Fernandes JF, Rocha V, Badell I, Ram R, Schiller GJ, Volodin L, Walters MC, Hamerschlak N, Cilloni D, Frankfurt O, McGuirk JP, Kurtzberg J, Sanz G, Simantov R, Horwitz ME (2023) Multicenter long-term follow-up of allogeneic hematopoietic cell transplantation with omidubicel: a pooled analysis of five prospective clinical trials. Transplant Cell Ther 29:338 e331-338 e336. https:\/\/doi.org\/10.1016\/j.jtct.2023.01.031","journal-title":"Transplant Cell Ther"},{"key":"3063_CR108","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, West ML, T\u00f8ndel C, Jovanovic A, Giraldo P, Vujkovac B, Geberhiwot T, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Hughes D (2023) Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis 18:332. https:\/\/doi.org\/10.1186\/s13023-023-02937-6","journal-title":"Orphanet J Rare Dis"},{"key":"3063_CR109","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S1474-4422(22)00517-8","volume":"22","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Croop R, Stock DA, Madonia J, Forshaw M, Lovegren M, Mosher L, Coric V, Goadsby PJ (2023) Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol 22:209\u2013217. https:\/\/doi.org\/10.1016\/S1474-4422(22)00517-8","journal-title":"Lancet Neurol"},{"key":"3063_CR110","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","volume":"5","author":"A Liu","year":"2022","unstructured":"Liu A, Zhao J, Shah M, Migliorati JM, Tawfik SM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB (2022) Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: design, development, and clinical studies. ACS Pharmacol Transl Sci 5:1007\u20131016. https:\/\/doi.org\/10.1021\/acsptsci.2c00110","journal-title":"ACS Pharmacol Transl Sci"},{"key":"3063_CR111","doi-asserted-by":"publisher","first-page":"175883592211136","DOI":"10.1177\/17588359221113694","volume":"14","author":"MR Lloyd","year":"2022","unstructured":"Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A (2022) Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol 14:17588359221113694. https:\/\/doi.org\/10.1177\/17588359221113694","journal-title":"Ther Adv Med Oncol"},{"key":"3063_CR112","doi-asserted-by":"publisher","first-page":"e2144178","DOI":"10.1001\/jamanetworkopen.2021.44178","volume":"5","author":"JK Mah","year":"2022","unstructured":"Mah JK, Clemens PR, Guglieri M, Smith EC, Finkel RS, Tulinius M, Nevo Y, Ryan MM, Webster R, Castro D, Kuntz NL, McDonald CM, Damsker JM, Schwartz BD, Mengle-Gaw LJ, Jackowski S, Stimpson G, Ridout DA, Ayyar-Gupta V, Baranello G, Manzur AY, Muntoni F, Gordish-Dressman H, Leinonen M, Ward LM, Hoffman EP, Dang UJ (2022) Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial. JAMA Netw Open 5:e2144178. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44178","journal-title":"JAMA Netw Open"},{"key":"3063_CR113","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","volume":"79","author":"A Markham","year":"2019","unstructured":"Markham A, Keam SJ (2019) Sotagliflozin: first global approval. Drugs 79:1023\u20131029. https:\/\/doi.org\/10.1007\/s40265-019-01146-5","journal-title":"Drugs"},{"key":"3063_CR114","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M (2021) Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet 397:892\u2013901. https:\/\/doi.org\/10.1016\/S0140-6736(21)00224-5","journal-title":"Lancet"},{"key":"3063_CR115","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ (2023) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22:185\u2013212. https:\/\/doi.org\/10.1038\/s41573-022-00612-2","journal-title":"Nat Rev Drug Discov"},{"key":"3063_CR116","doi-asserted-by":"publisher","first-page":"1167762","DOI":"10.3389\/fcell.2023.1167762","volume":"11","author":"JR Mendell","year":"2023","unstructured":"Mendell JR, Shieh PB, McDonald CM, Sahenk Z, Lehman KJ, Lowes LP, Reash NF, Iammarino MA, Alfano LN, Sabo B, Woods JD, Skura CL, Mao HC, Staudt LA, Griffin DA, Lewis S, Wang S, Potter RA, Singh T, Rodino-Klapac LR (2023) Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol 11:1167762. https:\/\/doi.org\/10.3389\/fcell.2023.1167762","journal-title":"Front Cell Dev Biol"},{"key":"3063_CR117","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V (2022) Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82:865\u2013887. https:\/\/doi.org\/10.1007\/s40265-022-01726-y","journal-title":"Drugs"},{"key":"3063_CR118","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1158\/1078-0432.CCR-14-0607","volume":"21","author":"WA Messersmith","year":"2015","unstructured":"Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM (2015) A phase I, dose-finding study in patients with advanced solid malignancies of the oral gamma-secretase inhibitor PF-03084014. Clin Cancer Res 21:60\u201367. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-0607","journal-title":"Clin Cancer Res"},{"key":"3063_CR119","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1080\/10428194.2021.1953016","volume":"62","author":"A Minson","year":"2021","unstructured":"Minson A, Dickinson M (2021) Glofitamab CD20-TCB bispecific antibody. Leuk Lymphoma 62:3098\u20133108. https:\/\/doi.org\/10.1080\/10428194.2021.1953016","journal-title":"Leuk Lymphoma"},{"key":"3063_CR120","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-023-00202-w","author":"A Mullard","year":"2023","unstructured":"Mullard A (2023) FDA approves first-in-class AKT inhibitor. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/d41573-023-00202-w","journal-title":"Nat Rev Drug Discov"},{"key":"3063_CR121","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, Fernandes SM, Saksena G, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Lederer JA, Zain R, Smith CIE, Leshchiner I, Parida L, Getz G, Brown JR (2023) Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv 7:1929\u20131943. https:\/\/doi.org\/10.1182\/bloodadvances.2022008447","journal-title":"Blood Adv"},{"key":"3063_CR122","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1080\/10428194.2019.1602263","volume":"60","author":"K Naqvi","year":"2019","unstructured":"Naqvi K, Ravandi F (2019) FLT3 inhibitor quizartinib (AC220). Leuk Lymphoma 60:1866\u20131876. https:\/\/doi.org\/10.1080\/10428194.2019.1602263","journal-title":"Leuk Lymphoma"},{"key":"3063_CR123","doi-asserted-by":"publisher","unstructured":"Nisar A, Ahmed Z, Yuan H (2023) Novel therapeutic targets for migraine. Biomedicines 11. https:\/\/doi.org\/10.3390\/biomedicines11020569","DOI":"10.3390\/biomedicines11020569"},{"key":"3063_CR124","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1056\/NEJMoa1615887","volume":"377","author":"A Ozen","year":"2017","unstructured":"Ozen A, Comrie WA, Ardy RC, Dom\u00ednguez Conde C, Dalgic B, Beser \u00d6F, Morawski AR, Karakoc-Aydiner E, Tutar E, Baris S, Ozcay F, Serwas NK, Zhang Y, Matthews HF, Pittaluga S, Folio LR, Unlusoy Aksu A, McElwee JJ, Krolo A, Kiykim A, Baris Z, Gulsan M, Ogulur I, Snapper SB, Houwen RHJ, Leavis HL, Ertem D, Kain R, Sari S, Erkan T, Su HC, Boztug K, Lenardo MJ (2017) CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N Engl J Med 377:52\u201361. https:\/\/doi.org\/10.1056\/NEJMoa1615887","journal-title":"N Engl J Med"},{"key":"3063_CR125","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cardfail.2023.08.003","volume":"29","author":"M Packer","year":"2023","unstructured":"Packer M (2023) Sotagliflozin for heart failure: what we know about trials and mechanisms. J Card Fail 29:1586\u20131588. https:\/\/doi.org\/10.1016\/j.cardfail.2023.08.003","journal-title":"J Card Fail"},{"key":"3063_CR126","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.tips.2023.06.008","volume":"44","author":"H Parent","year":"2023","unstructured":"Parent H, Ferranti A, Niswender C (2023) Trofinetide: a pioneering treatment for Rett syndrome. Trends Pharmacol Sci 44:740\u2013741. https:\/\/doi.org\/10.1016\/j.tips.2023.06.008","journal-title":"Trends Pharmacol Sci"},{"key":"3063_CR127","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood.2022017423","volume":"141","author":"F Passamonti","year":"2023","unstructured":"Passamonti F, Mora B (2023) Myelofibrosis. Blood 141:1954\u20131970. https:\/\/doi.org\/10.1182\/blood.2022017423","journal-title":"Blood"},{"key":"3063_CR128","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","volume":"37","author":"SS Patel","year":"2023","unstructured":"Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM (2023) Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond) 37:3551\u20133557. https:\/\/doi.org\/10.1038\/s41433-023-02497-w","journal-title":"Eye (Lond)"},{"key":"3063_CR129","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4762","volume":"38","author":"RJ Pignolo","year":"2023","unstructured":"Pignolo RJ, Hsiao EC, Al Mukaddam M, Baujat G, Berglund SK, Brown MA, Cheung AM, De Cunto C, Delai P, Haga N, Kannu P, Keen R, Le Quan Sang KH, Mancilla EE, Marino R, Strahs A, Kaplan FS (2023) Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 38:381\u2013394. https:\/\/doi.org\/10.1002\/jbmr.4762","journal-title":"J Bone Miner Res"},{"key":"3063_CR130","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.jchf.2023.05.026","volume":"11","author":"B Pitt","year":"2023","unstructured":"Pitt B, Bhatt DL, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Ezekowitz JA, Sun F, Davies MJ, Verma S, Kosiborod MN, Steg PG (2023) Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF. JACC Heart Fail 11:879\u2013889. https:\/\/doi.org\/10.1016\/j.jchf.2023.05.026","journal-title":"JACC Heart Fail"},{"key":"3063_CR131","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s00592-014-0627-6","volume":"51","author":"M Qi","year":"2014","unstructured":"Qi M, Kinzer K, Danielson KK, Martellotto J, Barbaro B, Wang Y, Bui JT, Gaba RC, Knuttinen G, Garcia-Roca R, Tzvetanov I, Heitman A, Davis M, McGarrigle JJ, Benedetti E, Oberholzer J (2014) Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience. Acta Diabetol 51:833\u2013843. https:\/\/doi.org\/10.1007\/s00592-014-0627-6","journal-title":"Acta Diabetol"},{"key":"3063_CR132","doi-asserted-by":"publisher","first-page":"203636132312074","DOI":"10.1177\/20363613231207483","volume":"15","author":"T Rais","year":"2023","unstructured":"Rais T, Khan A, Riaz R (2023) Elrexfio (elranatamab-bcmm): the game-changer in treatment of multiple myeloma. Rare Tumors 15:20363613231207484. https:\/\/doi.org\/10.1177\/20363613231207483","journal-title":"Rare Tumors"},{"key":"3063_CR133","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A, Plebani A, Schuetz C, Shcherbina A, Conlon N, Coulter T, Dalm VA, Trizzino A, Zharankova Y, Kulm E, K\u00f6rholz J, Lougaris V, Rodina Y, Radford K, Bradt J, Kucher K, Relan A, Holland SM, Lenardo MJ, Uzel G (2023) A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood 141:971\u2013983. https:\/\/doi.org\/10.1182\/blood.2022018546","journal-title":"Blood"},{"key":"3063_CR134","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s40259-019-00361-6","volume":"33","author":"J Reis","year":"2019","unstructured":"Reis J, Vender R, Torres T (2019) Bimekizumab: the first dual inhibitor of interleukin (IL)-17A and IL-17F for the treatment of psoriatic disease and ankylosing spondylitis. BioDrugs 33:391\u2013399. https:\/\/doi.org\/10.1007\/s40259-019-00361-6","journal-title":"BioDrugs"},{"key":"3063_CR135","doi-asserted-by":"publisher","first-page":"203636132311935","DOI":"10.1177\/20363613231193566","volume":"15","author":"R Riaz","year":"2023","unstructured":"Riaz R, Khan A, Siddiqui T (2023) Epcoritamab-bysp (Epkinly) - a phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma. Rare Tumors 15:20363613231193570. https:\/\/doi.org\/10.1177\/20363613231193566","journal-title":"Rare Tumors"},{"key":"3063_CR136","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1136\/ard-2023-224431","volume":"82","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Coates LC, McInnes IB, Mease PJ, Merola JF, Tanaka Y, Asahina A, Gossec L, Gottlieb AB, Warren RB, Ink B, Bajracharya R, Shende V, Coarse J, Landew\u00e9 RB (2023) Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study. Ann Rheum Dis 82:1404\u20131414. https:\/\/doi.org\/10.1136\/ard-2023-224431","journal-title":"Ann Rheum Dis"},{"key":"3063_CR137","doi-asserted-by":"publisher","first-page":"203636132311824","DOI":"10.1177\/20363613231182485","volume":"15","author":"S Rohail","year":"2023","unstructured":"Rohail S, Fareed A, Taimuri MA, Adnan A (2023) Nirogacestat and its potential impact on desmoid tumor. Rare Tumors 15:20363613231182484. https:\/\/doi.org\/10.1177\/20363613231182485","journal-title":"Rare Tumors"},{"key":"3063_CR138","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/s0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Ma\u0142ecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402:2077\u20132090. https:\/\/doi.org\/10.1016\/s0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"3063_CR139","doi-asserted-by":"publisher","first-page":"129121","DOI":"10.1016\/j.jtct.2022.11.007","volume":"29","author":"T Saiyin","year":"2023","unstructured":"Saiyin T, Kirkham AM, Bailey AJM, Shorr R, Pineault N, Maganti HB, Allan DS (2023) Clinical outcomes of umbilical cord blood transplantation using ex vivo expansion: a systematic review and meta-analysis of controlled studies. Transplant Cell Ther 29:129121\u2013129129. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.007","journal-title":"Transplant Cell Ther"},{"key":"3063_CR140","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/s0140-6736(23)00061-2","volume":"401","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D\u2019Haens G, Danese S, Goetsch M, Feagan BG (2023) Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet 401:1159\u20131171. https:\/\/doi.org\/10.1016\/s0140-6736(23)00061-2","journal-title":"Lancet"},{"key":"3063_CR141","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","volume":"26","author":"NS Sanghani","year":"2019","unstructured":"Sanghani NS, Haase VH (2019) Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis 26:253\u2013266. https:\/\/doi.org\/10.1053\/j.ackd.2019.04.004","journal-title":"Adv Chronic Kidney Dis"},{"key":"3063_CR142","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, Giraldo P, Barisoni L, Colvin RB, Jennette CJ, Maegawa G, Boyadjiev SA, Gonzalez D, Nicholls K, Tuffaha A, Atta MG, Rup B, Charney MR, Paz A, Szlaifer M, Alon S, Brill-Almon E, Chertkoff R, Hughes D (2019) Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year phase 1\/2 clinical trial. J Inherit Metab Dis 42:534\u2013544. https:\/\/doi.org\/10.1002\/jimd.12080","journal-title":"J Inherit Metab Dis"},{"key":"3063_CR143","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/s1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, Sitaraman S, Jiang H, Lafor\u00eat P, Toscano A, Castelli J, D\u00edaz-Manera J, Goldman M, van der Ploeg AT, Bratkovic D, Kuchipudi S, Mozaffar T, Kishnani PS (2021) Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol 20:1027\u20131037. https:\/\/doi.org\/10.1016\/s1474-4422(21)00331-8","journal-title":"Lancet Neurol"},{"key":"3063_CR144","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ajo.2023.03.008","volume":"252","author":"JD Sheppard","year":"2023","unstructured":"Sheppard JD, Kurata F, Epitropoulos AT, Kr\u00f6sser S, Vittitow JL (2023) NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol 252:265\u2013274. https:\/\/doi.org\/10.1016\/j.ajo.2023.03.008","journal-title":"Am J Ophthalmol"},{"key":"3063_CR145","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s40265-018-0998-z","volume":"78","author":"M Shirley","year":"2018","unstructured":"Shirley M (2018) Fruquintinib: first global approval. Drugs 78:1757\u20131761. https:\/\/doi.org\/10.1007\/s40265-018-0998-z","journal-title":"Drugs"},{"key":"3063_CR146","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-023-01894-5","volume":"83","author":"M Shirley","year":"2023","unstructured":"Shirley M (2023a) Glofitamab: first approval. Drugs 83:935\u2013941. https:\/\/doi.org\/10.1007\/s40265-023-01894-5","journal-title":"Drugs"},{"key":"3063_CR147","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01977-3","author":"M Shirley","year":"2023","unstructured":"Shirley M (2023b) Zilucoplan: first approval. Drugs. https:\/\/doi.org\/10.1007\/s40265-023-01977-3","journal-title":"Drugs"},{"key":"3063_CR148","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1111\/jdv.18914","volume":"37","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Bissonnette R, Kircik L, Murrell DF, Selfridge A, Liu K, Ahluwalia G, Guttman-Yassky E (2023) Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (ADVISE). J Eur Acad Dermatol Venereol 37:1366\u20131374. https:\/\/doi.org\/10.1111\/jdv.18914","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3063_CR149","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/19420862.2018.1505464","volume":"10","author":"B Smith","year":"2018","unstructured":"Smith B, Kiessling A, Lledo-Garcia R, Dixon KL, Christodoulou L, Catley MC, Atherfold P, D\u2019Hooghe LE, Finney H, Greenslade K, Hailu H, Kevorkian L, Lightwood D, Meier C, Munro R, Qureshi O, Sarkar K, Shaw SP, Tewari R, Turner A, Tyson K, West S, Shaw S, Brennan FR (2018) Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration. MAbs 10:1111\u20131130. https:\/\/doi.org\/10.1080\/19420862.2018.1505464","journal-title":"MAbs"},{"key":"3063_CR150","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","volume":"89","author":"B Strober","year":"2023","unstructured":"Strober B, Paul C, Blauvelt A, Tha\u00e7i D, Puig L, Lebwohl M, White K, Vanvoorden V, Deherder D, Gomez NN, Eyerich K (2023) Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. J Am Acad Dermatol 89:486\u2013495. https:\/\/doi.org\/10.1016\/j.jaad.2023.04.063","journal-title":"J Am Acad Dermatol"},{"key":"3063_CR151","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.eururo.2023.06.018","volume":"84","author":"DS Surasi","year":"2023","unstructured":"Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF (2023) Diagnostic performance and safety of positron emission tomography with (18)F-rhPSMA-7.3 in patients with newly diagnosed unfavourable intermediate- to very-high-risk prostate cancer: results from a phase 3, prospective, multicentre study (LIGHTHOUSE). Eur Urol 84:361\u2013370. https:\/\/doi.org\/10.1016\/j.eururo.2023.06.018","journal-title":"Eur Urol"},{"key":"3063_CR152","doi-asserted-by":"publisher","first-page":"1213920","DOI":"10.3389\/fimmu.2023.1213920","volume":"14","author":"GQ Tang","year":"2023","unstructured":"Tang GQ, Tang Y, Dhamnaskar K, Hoarty MD, Vyasamneni R, Vadysirisack DD, Ma Z, Zhu N, Wang JG, Bu C, Cong B, Palmer E, Duda PW, Sayegh C, Ricardo A (2023) Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation. Front Immunol 14:1213920. https:\/\/doi.org\/10.3389\/fimmu.2023.1213920","journal-title":"Front Immunol"},{"key":"3063_CR153","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ophtha.2022.12.021","volume":"130","author":"J Tauber","year":"2023","unstructured":"Tauber J, Berdy GJ, Wirta DL, Kr\u00f6sser S, Vittitow JL (2023) NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology 130:516\u2013524. https:\/\/doi.org\/10.1016\/j.ophtha.2022.12.021","journal-title":"Ophthalmology"},{"key":"3063_CR154","doi-asserted-by":"publisher","first-page":"e3647","DOI":"10.1093\/cid\/ciaa1380","volume":"73","author":"GR Thompson","year":"2021","unstructured":"Thompson GR, Soriano A, Skoutelis A, Vazquez JA, Honore PM, Horcajada JP, Spapen H, Bassetti M, Ostrosky-Zeichner L, Das AF, Viani RM, Sandison T, Pappas PG (2021) Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial. Clin Infect Dis 73:e3647\u2013e3655. https:\/\/doi.org\/10.1093\/cid\/ciaa1380","journal-title":"Clin Infect Dis"},{"key":"3063_CR155","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0140-6736(22)02324-8","volume":"401","author":"GR Thompson 3rd","year":"2023","unstructured":"Thompson GR 3rd, Soriano A, Cornely OA, Kullberg BJ, Kollef M, Vazquez J, Honore PM, Bassetti M, Pullman J, Chayakulkeeree M, Poromanski I, Dignani C, Das AF, Sandison T, Pappas PG (2023) Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. Lancet 401:49\u201359. https:\/\/doi.org\/10.1016\/s0140-6736(22)02324-8","journal-title":"Lancet"},{"key":"3063_CR156","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2217\/fon-2022-0276","volume":"18","author":"D Tremblay","year":"2022","unstructured":"Tremblay D, Mesa R (2022) Momelotinib for the treatment of myelofibrosis with anemia. Future Oncol 18:2559\u20132571. https:\/\/doi.org\/10.2217\/fon-2022-0276","journal-title":"Future Oncol"},{"key":"3063_CR157","unstructured":"U.S. Food and Drug Administration (2023a) https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products Accessed 23.12.2023"},{"key":"3063_CR158","unstructured":"U.S. Food and Drug Administration (2023b) https:\/\/www.fda.gov\/drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products\/novel-drug-approvals-2023. Accessed 29 Jan 2024"},{"key":"3063_CR159","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","volume":"5","author":"CPM Verkleij","year":"2021","unstructured":"Verkleij CPM, Broekmans MEC, van Duin M, Frerichs KA, Kuiper R, de Jonge AV, Kaiser M, Morgan G, Axel A, Boominathan R, Sendecki J, Wong A, Verona RI, Sonneveld P, Zweegman S, Adams HC, Mutis T, van de Donk N (2021) Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv 5:2196\u20132215. https:\/\/doi.org\/10.1182\/bloodadvances.2020003805","journal-title":"Blood Adv"},{"key":"3063_CR160","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1182\/bloodadvances.2022009311","volume":"7","author":"S Verstovsek","year":"2023","unstructured":"Verstovsek S, Mesa R, Gupta V, Lavie D, Dubruille V, Cambier N, Platzbecker U, Hus M, Xicoy B, Oh ST, Kiladjian JJ, Vannucchi AM, Gerds A, Egyed M, Mayer J, Sacha T, Kawashima J, Morris M, Huang M, Harrison C (2023) Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. Blood Adv 7:3582\u20133591. https:\/\/doi.org\/10.1182\/bloodadvances.2022009311","journal-title":"Blood Adv"},{"key":"3063_CR161","doi-asserted-by":"publisher","first-page":"S210","DOI":"10.1093\/cid\/ciad097","volume":"76","author":"RR Watkins","year":"2023","unstructured":"Watkins RR, Du B, Isaacs R, Altarac D (2023) Pathogen-targeted clinical development to address unmet medical need: design, safety, and efficacy of the ATTACK trial. Clin Infect Dis 76:S210-s214. https:\/\/doi.org\/10.1093\/cid\/ciad097","journal-title":"Clin Infect Dis"},{"key":"3063_CR162","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s13311-023-01405-0","volume":"20","author":"G Yadollahikhales","year":"2023","unstructured":"Yadollahikhales G, Rojas JC (2023) Anti-amyloid immunotherapies for Alzheimer\u2019s disease: a 2023 clinical update. Neurotherapeutics 20:914\u2013931. https:\/\/doi.org\/10.1007\/s13311-023-01405-0","journal-title":"Neurotherapeutics"},{"key":"3063_CR163","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/ico.0000000000003097","volume":"42","author":"E Yeu","year":"2023","unstructured":"Yeu E, Wirta DL, Karpecki P, Baba SN, Holdbrook M (2023) Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (saturn-1). Cornea 42:435\u2013443. https:\/\/doi.org\/10.1097\/ico.0000000000003097","journal-title":"Cornea"},{"key":"3063_CR164","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","volume":"26","author":"MR Yun","year":"2020","unstructured":"Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC (2020) Repotrectinib exhibits potent antitumor activity in treatment-naive and solvent-front-mutant ROS1-rearranged non-small cell lung cancer. Clin Cancer Res 26:3287\u20133295. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2777","journal-title":"Clin Cancer Res"},{"key":"3063_CR165","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/jpem-2022-0359","volume":"36","author":"Z Zadik","year":"2023","unstructured":"Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, Valluri SR, Pastrak A, Rosenfeld R (2023) An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab 36:261\u2013269. https:\/\/doi.org\/10.1515\/jpem-2022-0359","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3063_CR166","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1002\/ana.26755","volume":"94","author":"CM Zaidman","year":"2023","unstructured":"Zaidman CM, Proud CM, McDonald CM, Lehman KJ, Goedeker NL, Mason S, Murphy AP, Guridi M, Wang S, Reid C, Darton E, Wandel C, Lewis S, Malhotra J, Griffin DA, Potter RA, Rodino-Klapac LR, Mendell JR (2023) Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR). Ann Neurol 94:955\u2013968. https:\/\/doi.org\/10.1002\/ana.26755","journal-title":"Ann Neurol"},{"key":"3063_CR167","doi-asserted-by":"publisher","first-page":"730666","DOI":"10.3389\/fimmu.2021.730666","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang L, Hao B, Geng Z, Geng Q (2021) Toripalimab: the first domestic anti-tumor PD-1 antibody in China. Front Immunol 12:730666. https:\/\/doi.org\/10.3389\/fimmu.2021.730666","journal-title":"Front Immunol"},{"key":"3063_CR168","doi-asserted-by":"publisher","first-page":"166907","DOI":"10.1016\/j.bbadis.2023.166907","volume":"1870","author":"C Zheng","year":"2024","unstructured":"Zheng C, Huang J, Xu G, Li W, Weng X, Zhang S (2024) The Notch signaling pathway in desmoid tumor: recent advances and the therapeutic prospects. Biochim Biophys Acta Mol Basis Dis 1870:166907. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166907","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03063-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T06:39:48Z","timestamp":1714977588000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":168,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["3063"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03063-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GKM, ZSA, and LW declare no conflict of interest. MCM is a consultant and\/or speaker for Apogepha, Astellas, Dr. Willmar Schwabe, Eli Lilly, GSK, Labatec, MIP Pharma, and Sanofi-Aventis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}